All sponsors

Nuvation Bio Inc. $NUVB

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING4
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO33%

Delay Index: of 6 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.3 months). See all sponsors →

Open Nuvation Bio Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
AB-106
NCT04395677
P2Active, not recruitingNon Small Cell Lung Cancer1732024-06-07 (+20 mo)
TRUST-II
NCT04919811
P2Active, not recruitingNon Small Cell Lung Cancer2172025-06-11
NUV-1511
NCT06334432
P1/2Active, not recruitingAdvanced Solid Tumor; HER2-negative Breast Cancer4662027-03
SIGMA
NCT05303519
P3RecruitingGlioma; Astrocytoma, Grade IV3652028-12-01 (+35 mo)
Taletrectinib
NCT06564324
P3RecruitingNon Small Cell Lung Cancer1942029-01
Safusidenib
NCT07712757
P3Not yet recruitingGrade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation; Astrocytoma IDH Mutant Grade 21402029-05
Taletrectinib
NCT07154706
P3RecruitingNon-small Cell Lung Cancer (NSCLC)1802030-08-30
Safusidenib
NCT07703436
P2RecruitingGrade 2 IDH1-mutant Glioma; Grade 3 IDH1-mutant Glioma402030-09